ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the
safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT)
administered intravenously in adults with advanced non-small cell lung cancer (NSCLC).